Literature DB >> 30703415

Sarcolemmal α2-adrenoceptors in feedback control of myocardial response to sympathetic challenge.

Alexey E Alekseev1, Sungjo Park2, Oleg Yu Pimenov3, Santiago Reyes2, Andre Terzic2.   

Abstract

α2-adrenoceptor (α2-AR) isoforms, abundant in sympathetic synapses and noradrenergic neurons of the central nervous system, are integral in the presynaptic feed-back loop mechanism that moderates norepinephrine surges. We recently identified that postsynaptic α2-ARs, found in the myocellular sarcolemma, also contribute to a muscle-delimited feedback control capable of attenuating mobilization of intracellular Ca2+ and myocardial contractility. This previously unrecognized α2-AR-dependent rheostat is able to counteract competing adrenergic receptor actions in cardiac muscle. Specifically, in ventricular myocytes, nitric oxide (NO) and cGMP are the intracellular messengers of α2-AR signal transduction pathways that gauge the kinase-phosphatase balance and manage cellular Ca2+ handling preventing catecholamine-induced Ca2+ overload. Moreover, α2-AR signaling counterbalances phospholipase C - PKC-dependent mechanisms underscoring a broader cardioprotective potential under sympathoadrenergic and angiotensinergic challenge. Recruitment of such tissue-specific features of α2-AR under sustained sympathoadrenergic drive may, in principle, be harnessed to mitigate or prevent cardiac malfunction. However, cardiovascular disease may compromise peripheral α2-AR signaling limiting pharmacological targeting of these receptors. Prospective cardiac-specific gene or cell-based therapeutic approaches aimed at repairing or improving stress-protective α2-AR signaling may offer an alternative towards enhanced preservation of cardiac muscle structure and function.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Ca(2+) handling; Cardioprotection; Catecholamine; Cell signaling; G-protein coupled receptors; Heart failure

Mesh:

Substances:

Year:  2019        PMID: 30703415     DOI: 10.1016/j.pharmthera.2019.01.007

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  2 in total

1.  Novel Substituted Heterocyclic Carboxamides as Adrenoreceptor ADRAC2 Inhibitors for Treating Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-08-17       Impact factor: 4.632

Review 2.  Upregulation of Phospholipase C Gene Expression Due to Norepinephrine-Induced Hypertrophic Response.

Authors:  Paramjit S Tappia; Naranjan S Dhalla
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.